Minerva NeurosciencesNERV
About: Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
Employees: 9
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0.3% more ownership
Funds ownership: 30.0% [Q2] → 30.3% (+0.3%) [Q3]
0% more funds holding
Funds holding: 21 [Q2] → 21 (+0) [Q3]
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
15% less capital invested
Capital invested by funds: $6.69M [Q2] → $5.65M (-$1.03M) [Q3]
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Douglas Tsao 43% 1-year accuracy 71 / 167 met price target | 131%upside $5 | Neutral Reiterated | 6 Nov 2024 |